Citi Analyst Boosts Abbott Price Target Ahead of Q2 Earnings

Citi analyst Joanne Wuensch has raised Abbott's (ABT) price target to $157 from $155, maintaining a Buy rating. Abbott's Q1 earnings beat expectations with 6.9% sales growth and 11% EPS growth. The nutrition segment saw a 7% sales increase, while diagnostics sales declined 5%. The analyst's optimism reflects Abbott's strong financial performance and market positioning.

Abbott Laboratories (ABT) reported strong quarterly earnings for the first quarter of 2025, beating market expectations and prompting a price target increase from Citi analyst Joanne Wuensch. The company reported a 6.9% increase in sales and an 11% growth in earnings per share (EPS) compared to the same period last year [2].

The nutrition segment contributed significantly to the growth, with a 7% sales increase. However, diagnostics sales declined by 5%, reflecting the ongoing challenges in this segment. Despite these fluctuations, the overall performance was robust, underscoring Abbott's strong market positioning and strategic initiatives.

Citi analyst Joanne Wuensch, who maintains a Buy rating on the stock, has raised the price target for Abbott Laboratories to $157 from $155. This move reflects the analyst's optimism about the company's financial performance and market prospects. The analyst's positive outlook is supported by Abbott's strong operational momentum and favorable market conditions [2].

The earnings report and the subsequent price target increase highlight Abbott Laboratories' resilience and growth potential. Investors should closely monitor the company's future earnings announcements and strategic developments for further insights into its financial trajectory.

References:
[1] https://finance.yahoo.com/news/karooooo-ltd-karo-report-q1-140007824.html
[2] https://www.tipranks.com/stocks/abt/forecast